PLGA–Soya Lecithin Based Hybrid Nanocomposite for Targeted Topical Delivery of Resveratrol in Psoriasis Management
April 2025
New to Resveratrol? There is a guide in the encyclopedia. Read the guide → Studysummary This study developed a nanocarrier-based gel to enhance the delivery and effectiveness of resveratrol in treating psoriasis. In a mouse model, the gel improved skin penetration and retention, showed notable anti-psoriatic effects, and was deemed safe and biocompatible.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The study presents a novel nanocarrier-based strategy for psoriasis management using a hybrid nanocomposite of soya lecithin and PLGA to deliver resveratrol (RSV). The developed formulation, RSVNPGel, demonstrated improved physicochemical properties, including enhanced skin penetration and adhesiveness. In an imiquimod-induced psoriatic mouse model, RSVNPGel significantly reduced epidermal thickness and inflammatory cell infiltration, indicating its potential efficacy in treating psoriasis. The formulation also showed excellent safety and biocompatibility, suggesting it could be an effective topical treatment option that minimizes systemic exposure.
